Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A First-in-human, Multicenter, Open-label, Phase 1 Study in Patients With Advanced and/or Refractory Solid Malignancies to Evaluate the Safety of Intravenously Administered ATOR-1015

NCT03782467 is registered in ClinicalTrials.gov with Alligator Bioscience AB as lead sponsor.

NCT NCT03782467
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03782467 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A First-in-human, Multicenter, Open-label, Phase 1 Study in Patients With Advanced and/or Refractory Solid Malignancies to Evaluate the Safety of Intravenously Administered ATOR-1015
Lead sponsor
Alligator Bioscience AB
Phase
Phase 1
Overall status
Completed
Start date
January 30, 2019
Completion date
March 3, 2021
Enrollment
33 (actual)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

neoplasms, solid tumor